Masspec Pen Evaluated for Rapid Diagnosis of Cancer
By LabMedica International staff writers Posted on 20 Jun 2019 |
The handheld MasSpec Pen device which can be connected to a Mass Spectrometer for diagnosing ovarian and other cancers (Photo courtesy of the University of Texas at Austin).
Ovarian cancer is a highly lethal disease and the fifth leading cause of all cancer-related deaths in women. Accurate diagnosis and stratification of ovarian cancer is important to develop personalized treatment approaches.
Current methods for intraoperative tissue evaluation can be time intensive and subjective. A handheld and biocompatible device coupled to a mass spectrometer, has been developed, which uses a discrete water droplet for molecular extraction and rapid tissue diagnosis.
Scientists at The University of Texas at Austin (Austin, TX, USA) used the devise called the MasSpec Pen to analyze its performance on 192 ovarian, fallopian tube, and peritoneum tissue samples. The analyzed area of the tissue was demarcated and registered through optical images. Demarcated tissue or a parallel piece was frozen and sectioned at 10–16 μm using a CryoStar NX50 cryostat (Thermo Fisher Scientific, Waltham MA, USA), stained by standard hematoxylin and eosin procedure, and evaluated by expert pathologists to confirm diagnosis of the analyzed area. Performance using an Orbitrap and a linear ion trap mass spectrometer was tested. Of note, the final diagnoses were performed after MasSpec Pen analyses. Only 164 samples with clear diagnosis were used for statistical analysis.
The team reported that a high performance for 131 high-grade serous carcinoma (clinical sensitivity, 96.7%; specificity, 95.7%) and 138 overall cancer (clinical sensitivity, 94.0%; specificity, 94.4%) diagnoses was achieved using Orbitrap data. Discrimination between cancer and fallopian tube or peritoneum tissues was also achieved with accuracies of 92.6% and 87.9%, respectively, and 100% clinical specificity for both. Using ion trap data, excellent results for high-grade serous cancer versus normal ovarian differentiation were achieved.
The authors concluded that the MasSpec Pen, together with machine learning, provides robust molecular models for ovarian serous cancer prediction and thus has potential for clinical use for rapid and accurate ovarian cancer diagnosis. The study was published in the May 2019 issue of the journal Clinical Chemistry.
Related Links:
The University of Texas at Austin
Thermo Fisher Scientific
Current methods for intraoperative tissue evaluation can be time intensive and subjective. A handheld and biocompatible device coupled to a mass spectrometer, has been developed, which uses a discrete water droplet for molecular extraction and rapid tissue diagnosis.
Scientists at The University of Texas at Austin (Austin, TX, USA) used the devise called the MasSpec Pen to analyze its performance on 192 ovarian, fallopian tube, and peritoneum tissue samples. The analyzed area of the tissue was demarcated and registered through optical images. Demarcated tissue or a parallel piece was frozen and sectioned at 10–16 μm using a CryoStar NX50 cryostat (Thermo Fisher Scientific, Waltham MA, USA), stained by standard hematoxylin and eosin procedure, and evaluated by expert pathologists to confirm diagnosis of the analyzed area. Performance using an Orbitrap and a linear ion trap mass spectrometer was tested. Of note, the final diagnoses were performed after MasSpec Pen analyses. Only 164 samples with clear diagnosis were used for statistical analysis.
The team reported that a high performance for 131 high-grade serous carcinoma (clinical sensitivity, 96.7%; specificity, 95.7%) and 138 overall cancer (clinical sensitivity, 94.0%; specificity, 94.4%) diagnoses was achieved using Orbitrap data. Discrimination between cancer and fallopian tube or peritoneum tissues was also achieved with accuracies of 92.6% and 87.9%, respectively, and 100% clinical specificity for both. Using ion trap data, excellent results for high-grade serous cancer versus normal ovarian differentiation were achieved.
The authors concluded that the MasSpec Pen, together with machine learning, provides robust molecular models for ovarian serous cancer prediction and thus has potential for clinical use for rapid and accurate ovarian cancer diagnosis. The study was published in the May 2019 issue of the journal Clinical Chemistry.
Related Links:
The University of Texas at Austin
Thermo Fisher Scientific
Latest Pathology News
- Use of DICOM Images for Pathology Diagnostics Marks Significant Step towards Standardization
- First of Its Kind Universal Tool to Revolutionize Sample Collection for Diagnostic Tests
- AI-Powered Digital Imaging System to Revolutionize Cancer Diagnosis
- New Mycobacterium Tuberculosis Panel to Support Real-Time Surveillance and Combat Antimicrobial Resistance
- New Method Offers Sustainable Approach to Universal Metabolic Cancer Diagnosis
- Spatial Tissue Analysis Identifies Patterns Associated With Ovarian Cancer Relapse
- Unique Hand-Warming Technology Supports High-Quality Fingertip Blood Sample Collection
- Image-Based AI Shows Promise for Parasite Detection in Digitized Stool Samples
- Deep Learning Powered AI Algorithms Improve Skin Cancer Diagnostic Accuracy
- Microfluidic Device for Cancer Detection Precisely Separates Tumor Entities
- Virtual Skin Biopsy Determines Presence of Cancerous Cells
- AI Detects Viable Tumor Cells for Accurate Bone Cancer Prognoses Post Chemotherapy
- First Ever Technique Identifies Single Cancer Cells in Blood for Targeted Treatments
- Innovative Blood Collection Device Overcomes Common Obstacles Related to Phlebotomy
- Intra-Operative POC Device Distinguishes Between Benign and Malignant Ovarian Cysts within 15 Minutes
- Simple Skin Biopsy Test Detects Parkinson’s and Related Neurodegenerative Diseases